Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Other Accumulated Expenses (2016 - 2024)

Historic Other Accumulated Expenses for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to $3.0 million.

  • Trinity Biotech's Other Accumulated Expenses rose 414.78% to $3.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.0 million, marking a year-over-year increase of 414.78%. This contributed to the annual value of $3.0 million for FY2024, which is 414.78% up from last year.
  • According to the latest figures from Q4 2024, Trinity Biotech's Other Accumulated Expenses is $3.0 million, which was up 414.78% from $1.8 million recorded in Q3 2024.
  • Trinity Biotech's Other Accumulated Expenses' 5-year high stood at $69.3 million during Q4 2020, with a 5-year trough of $1.8 million in Q1 2024.
  • For the 5-year period, Trinity Biotech's Other Accumulated Expenses averaged around $17.0 million, with its median value being $13.0 million (2022).
  • As far as peak fluctuations go, Trinity Biotech's Other Accumulated Expenses surged by 787.14% in 2020, and later crashed by 8353.63% in 2024.
  • Quarter analysis of 5 years shows Trinity Biotech's Other Accumulated Expenses stood at $69.3 million in 2020, then dropped by 0.79% to $68.8 million in 2021, then plummeted by 82.16% to $12.3 million in 2022, then crashed by 76.61% to $2.9 million in 2023, then rose by 4.15% to $3.0 million in 2024.
  • Its Other Accumulated Expenses was $3.0 million in Q4 2024, compared to $1.8 million in Q3 2024 and $1.8 million in Q2 2024.